--- title: "JAN BIOTECH, INC. — Capability Statement" uei: "DKDUTDKCJQE6" cage: "71ZJ8" canonical: "https://teamingindex.com/contractor/DKDUTDKCJQE6/capability.md" html_url: "https://teamingindex.com/contractor/DKDUTDKCJQE6" updated: "2026-11-09T17:28:18.052Z" generator: "TeamingIndex capability twin 1.0" legal_name: "JAN BIOTECH, INC." dba_name: "JBI" primary_naics: "541714" sam_status: "active" active_exclusion: false claimed: false tier: "unclaimed" --- # JAN BIOTECH, INC. > JAN BIOTECH, INC. (DBA JBI) is a SAM.gov-registered entity based in ITHACA, NY 14850-1294. UEI DKDUTDKCJQE6; CAGE 71ZJ8; primary NAICS 541714. Compliance posture not provided. Active SAM registration. > **Unclaimed profile:** seeded from SAM.gov and USAspending public records. The entity has not claimed it, so capabilities and compliance posture have not been provided. ## Identifiers - **Legal business name:** JAN BIOTECH, INC. - **DBA name:** JBI - **UEI (SAM.gov Unique Entity ID):** DKDUTDKCJQE6 - **CAGE code:** 71ZJ8 - **Entity structure:** Corporate Entity (Not Tax Exempt) - **State of incorporation:** NY - **Website:** - **TeamingIndex profile:** - **Profile status:** Unclaimed · seeded from SAM.gov and USAspending public records ## Location - **Physical address (city, state, ZIP):** ITHACA, NY 14850-1294 - **Country:** United States - **Congressional district:** NY-19 ## NAICS & PSC | NAICS | Title | Primary | Small under SBA size standard (SAM.gov) | | --- | --- | --- | --- | | 541714 | Research and Development in Biotechnology (except Nanobiotechnology) | Yes | Yes | | 541690 | Other Scientific and Technical Consulting Services | No | Yes | | PSC | Name | | --- | --- | | 6550 | IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | - **PSC names:** Acquisition.gov PSC Manual (April 2025 edition) Size status is NAICS-specific and reflects the entity’s SAM.gov representations; check it against the size standard of the solicitation’s NAICS code. ## Socio-economic status - Small Business (SB) - Women-Owned Small Business (WOSB) Source: SAM.gov entity registration, synced 2026-11-09. Confirm current SBA certification (8(a), HUBZone, WOSB/EDWOSB, VetCert SDVOSB/VOSB) before relying on a status for a set-aside. ## SAM registration & exclusion screening - **Registration:** Active SAM registration - **Registration expires:** 2027-08-06 - **Registration activated:** 2026-08-21 - **Exclusion screening (FAR subpart 9.4):** No active exclusion recorded in SAM.gov - **Teaming eligibility:** Eligible to be proposed as a team member (active registration, no exclusion) - **Source:** SAM.gov Entity Management, synced 2026-11-09 ## Compliance posture Compliance posture not provided by the contractor. - Facility clearance: visible to paid members - Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). ## Contract vehicles No contract vehicle holdings on file. ## Past performance - **Total obligated, trailing 36 months (USAspending.gov):** $3,000,000 - **Award history:** 1 award on record - **Top funding agencies:** Defense Health Agency Showing the 1 award on record. | Award PIID | Agency | NAICS / PSC | Obligated | Base + all options | Period of performance | Set-aside | Place of performance | Description | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | HT942524C0079 | Department of Defense / Defense Health Agency | 541715 / AN12 | $3,000,000 | — | 2024-09-20 → 2027-01-19 | — | NY | DHA SBIR DIRECT PHASE II H2D-0219 SAMPLE COLLECTION AND PROCESSING METHODS TO SUPPORT BATTLEFIELD WOUND INFECTION DIAGNOSTICS | ## Proven teaming graph - No first-tier sub-award reports name this company yet - Source: USAspending.gov sub-award reports (FSRS), sync date not recorded. Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values. ## SBIR/STTR portfolio - SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects - 11 SBIR/STTR awards totaling $11.9M: SBIR Phase I 4, SBIR Phase II 4, STTR Phase I 2, STTR Phase II 1 - By agency: Department of Health and Human Services 8, Department of Defense 3 - Active projects (contract end date ahead): 2 - Phase II awards ending within 12 months: 1 - SBIR Phase II, Department of Health and Human Services (National Institutes of Health), 2025, Aug 21, 2025 to Jul 31, 2028: Sequence-based RNA Fluorescence Assay to Measure Latent HIV Reservoirs ($1,000,000) - SBIR Phase II (Direct to Phase II), Department of Defense (Defense Health Agency), 2024, Sep 12, 2024 to Jan 19, 2027: Sample Collection and Processing Methods to Support Battlefield Wound Infection Diagnostics ($3,000,000) - SBIR Phase I, Department of Health and Human Services (National Institutes of Health), 2023, Sep 1, 2023 to Aug 31, 2024: Pediatric Latent HIV Reservoir Characterization and Quantification Assay ($300,000) - SBIR Phase I, Department of Health and Human Services (Centers for Disease Control and Prevention), 2022, Sep 30, 2022 to Mar 31, 2023: Rapid COVID-19 Mutation Discrimination Test for Global SARS-CoV-2 Variant Surveillance ($275,766) - SBIR Phase II, Department of Health and Human Services (National Institutes of Health), 2022, Feb 3, 2022 to Jan 31, 2024: Sequence-based RNA Fluorescence Assay to Measure Latent HIV Reservoirs ($2,291,256) - STTR Phase II, Department of Defense (Army), 2020, Nov 21, 2019 to Nov 30, 2021: Hybrid Nano-Bio-Electronic Odor Detector ($1,000,000) - STTR Phase I, Department of Defense (Army), 2019, Dec 13, 2018 to Jun 12, 2019: Hybrid Nano-Bio-Electronic Odor Detector ($150,000) - SBIR Phase II, Department of Health and Human Services (National Institutes of Health), 2017, Aug 1, 2017 to Jul 31, 2020: Real-Time Spliced-RNA Detection to Quantify Latent HIV-Infected Cells in HAART Patients ($2,997,824) - SBIR Phase I, Department of Health and Human Services (National Institutes of Health), 2016, Jun 15, 2016 to Nov 30, 2017: Development of a Control Kit for Latent HIV Diagnostics ($288,893) - SBIR Phase I, Department of Health and Human Services (National Institutes of Health), 2015, Aug 15, 2015 to Feb 14, 2017: Point-of-Care Spliced RNA Diagnostic for Oral Detection of Replication-Competent Latent HIV-1 Infection ($213,238) - Phase III: Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual. - Source: SBIR.gov award data file, as of Nov 12, 2026 (file published Nov 1, 2026) ## FedRAMP offerings - No FedRAMP Marketplace listing is linked to this company - Source: FedRAMP Marketplace, sync date not recorded ## Exclusions & screening - Not yet checked against SAM.gov exclusions (search exclusions on SAM.gov: https://sam.gov/search/?index=ex) - Source: SAM.gov Exclusions, sync date not recorded - No confirmed match on the Consolidated Screening List (screened Nov 13, 2026) ## Contract vehicles on federal record - No contract-vehicle seats on federal record are linked to this company ## GSA CALC+ rates - No GSA CALC+ awarded ceiling rates on record for this company - Source: GSA CALC+ awarded ceiling rates, sync date not recorded. Ceiling rates are the most an agency can be charged, not prices paid ## Capabilities & differentiators No capability narrative published. ## Technical tags No technical tags published. ## Teaming preferences - Teaming preferences not published - **Teaming requests and NDAs:** request an introduction on the TeamingIndex profile (sign-in required): ## Business development contact No business-development contact published. ## Corporate hierarchy - No parent entity reported in SAM.gov - Affiliation with a parent or sister concerns can affect small-business size status (13 CFR 121.103). ## Provenance & disclaimer - **SAM.gov entity registration** (identifiers, NAICS/PSC, size and socio-economic status, hierarchy, registration and exclusion status): synced 2026-11-09 - **USAspending.gov** (prime award history and trailing 36-month obligations): nightly sync - **Contractor-provided profile** (capabilities, teaming preferences, self-attested compliance): not provided - **TeamingIndex verification** (credentials marked “Verified by TeamingIndex”): no verified credentials on record; methodology: - **Blind SPRS:** exact NIST SP 800-171 SPRS scores are published only when the contractor opts in; brackets are cumulative thresholds (SPRS ≥ 0, SPRS ≥ 50, SPRS ≥ 70, SPRS ≥ 85, SPRS ≥ 95, SPRS ≥ 105, SPRS = 110 (perfect)). - **Before award:** self-attested facts have not been independently verified. Confirm registration and exclusions in SAM.gov, CMMC status and SPRS assessment currency with the contractor (DFARS 252.204-7019, -7020 and -7021), facility clearances through DCSA’s NISS, AS9100-series certificates in the IAQG OASIS database, and FedRAMP authorizations on the FedRAMP Marketplace. - **Zero CUI:** this document contains no Controlled Unclassified Information. TeamingIndex stores verification metadata only, never SSPs, POA&Ms or DD Form 254s. - **Machine-readable:** schema.org JSON-LD is embedded in ; this twin: ; site index: © 2026 HILARTECH, LLC. All rights reserved. TeamingIndex.com is an independent defense industrial base intelligence platform owned and operated by HILARTECH, LLC and is not affiliated with or endorsed by the U.S. Department of Defense (DoD), the General Services Administration (GSA), or SAM.gov.